When administered by SIACI, bevacizumab, an anti-vascular endothelial growth factor (VEGF) mAb, has been associated with a good safety profile and some cases of tumor regression in patients with recurrent gliomas [43,44]. This evidence concerns the gene VEGFA and glioma.